Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
  di: Mitsuhiro Shikamura, et al.
  Pubblicazione: (2024)
• Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
  di: Hsiao‐Ling Chen, et al.
  Pubblicazione: (2024)
• Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study
  di: Wang‐Choi Tang, et al.
  Pubblicazione: (2025)
• Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
  di: Wenxiao Fan, et al.
  Pubblicazione: (2025)
• Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study
  di: Jacopo Bonet, et al.
  Pubblicazione: (2024)